Literature DB >> 26455561

Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin.

Federico Perosa1, Marcella Prete2, Giuseppe Di Lernia3, Carmela Ostuni4, Elvira Favoino3, Gabriele Valentini5.   

Abstract

Systemic sclerosis (SSc) is systemic, autoimmune, connective tissue disorder characterized by vascular abnormalities, collagen deposition (fibrosis), and the production of autoantibodies to nuclear proteins. About 20%-40% of patients have antibodies to centromere protein (CENP)-A or -B. Despite the known association of anti-CENP antibodies with certain clinical features of SSc, the role of these antibodies in SSc physiopathology is still poorly understood. To better understand the clinical significance and origin of these antibodies, we and others have been studying the epitopic motifs (amino acid contact sites) on CENP-A with the aim of determining whether other proteins can prime or be targeted by them. Here, we review published and ongoing studies aimed at defining the fine specificity and origin of anti-CENP-A antibodies. We describe progress made in identifying the CENP-A epitopic motif amino acids, and the discovery of one of these motifs in forkhead box protein E3 (FOXE-3), a transcription factor previously studied only for its role in the development of lens fiber cells. Moreover, we discuss preliminary evidence for a possible role of FOXE-3 in SSc pathogenesis and for the association of different subsets of anti-CENP-A antibodies, heterogeneously expressed among SSc patients, with some clinical correlates.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody; Centromere protein A; Epitope; Forkhead box protein E3; Motif; Phage display peptide library; Systemic sclerosis

Mesh:

Substances:

Year:  2015        PMID: 26455561     DOI: 10.1016/j.autrev.2015.10.001

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  7 in total

Review 1.  Pathogenesis of systemic sclerosis-current concept and emerging treatments.

Authors:  Masutaka Furue; Chikage Mitoma; Hiroki Mitoma; Gaku Tsuji; Takahito Chiba; Takeshi Nakahara; Hiroshi Uchi; Takafumi Kadono
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

Review 2.  Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells.

Authors:  Konstantinos Melissaropoulos; George Iliopoulos; Lazaros I Sakkas; Dimitrios Daoussis
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

Review 3.  Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis.

Authors:  Alexandre T J Maria; Marie Maumus; Alain Le Quellec; Christian Jorgensen; Danièle Noël; Philippe Guilpain
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

Review 4.  Molecular characteristics and functional differences of anti-PM/Scl autoantibodies and two other distinct and unique supramolecular structures known as "EXOSOMES".

Authors:  Peter J Wermuth; Sergio A Jimenez
Journal:  Autoimmun Rev       Date:  2020-08-12       Impact factor: 9.754

5.  Apoptosis-induced translocation of centromere protein F in its corresponding autoantibody production in hepatocellular carcinoma.

Authors:  Xiaojin Li; Yanmeng Li; Anjian Xu; Donghu Zhou; Bei Zhang; Saiping Qi; Zhibin Chen; Xiaoming Wang; Xiaojuan Ou; Bangwei Cao; Chunfeng Qu; Jian Huang
Journal:  Oncoimmunology       Date:  2021-10-18       Impact factor: 8.110

6.  Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease.

Authors:  Federico Perosa; Elvira Favoino; Isabella Eleonora Favia; Serena Vettori; Marcella Prete; Addolorata Corrado; Francesco Paolo Cantatore; Gabriele Valentini
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

Review 7.  Epigenetic Regulations of AhR in the Aspect of Immunomodulation.

Authors:  Anna Wajda; Joanna Łapczuk-Romańska; Agnieszka Paradowska-Gorycka
Journal:  Int J Mol Sci       Date:  2020-09-03       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.